scorecardresearch
Follow Us:
Sunday, August 01, 2021

Ocugen selects Jubilant HollisterStier as manufacturer for Covaxin in US

The US Food and Drug Administration recently 'recommended' Ocugen to pursue Biologics License Application (BLA) route for Covaxin instead of Emergency Use Authorisation (EUA).

By: PTI |
June 16, 2021 12:27:39 pm
Covid19 vaccine, Covaxin news, US, Bharat biotech, World news, Jubilant HollisterStier, Ocugen, Indian ExpressBharat Biotech has entered into a definitive agreement with OcugenInc, a US-based biopharmaceutical company, to co-develop, supply, and commercialise, its Covaxin for the American and Canadian markets. (File photo)

Ocugen Inc, Bharat Biotech’s US and Canada partner for its COVID-19 vaccine Covaxin, said it has chosen Jubilant HollisterStier of Spokane,Washington as its manufacturing partner for the vaccine for the North American countries.

“We are fully committed to bringing Covaxin to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants, J P Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain said in a release on Tuesday.

Bharat Biotech has entered into a definitive agreement with OcugenInc, a US-based biopharmaceutical company, to co-develop, supply, and commercialise, its Covaxin for the American and Canadian markets.

The US Food and Drug Administration recently ‘recommended’ Ocugen to pursue Biologics License Application (BLA) route for Covaxin instead of Emergency Use Authorisation (EUA).

“Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory
submissions to the FDA and Health Canada.

Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and
Jubilants proven track record in manufacturing, we are well-prepared to transition US manufacturing of Covaxin to our new partner” Gabriel further said.

With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, Jubilant remains committed to supporting efforts to eradicate this global pandemic, Pramod Yadav, CEO Jubilant Pharma Limited said.

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest World News, download Indian Express App.

  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement

Advertisement
Advertisement
Advertisement